Disease relevance of Ly6i

• Analysis of variants of the CH27 B cell lymphoma revealed that Ly-6A/E and Ly-6I recognized different molecules [1].

High impact information on Ly6i

• Characterization of Ly-6M, a novel member of the Ly-6 family of hematopoietic proteins [2].
• Ly-6M is broadly distributed in the bone marrow, with prominent expression on monocytes and myeloid precursors [2].
• Ly-6M protein is detectable on 10% to 15% of peripheral blood leukocytes, including monocytes and a subpopulation of B220(+) cells [2].
• Ly-6M messenger RNA (mRNA) is easily detectable in hematopoietic tissue (bone marrow, spleen, thymus, peritoneal macrophages) as well as kidney and lung [2].
• The identification and characterization of Ly-6M adds a new member to a complex family of homologous, tightly linked genes that have proven extremely useful reagents for defining populations within the hematopoietic system [2].

Anatomical context of Ly6i

• Ly-6I is re-expressed on Ly-6Chigh T cells in the periphery [3].
• Thus, Ly-6I may be a useful marker to define maturation stages of both T and B lymphocytes as well as subsets of monocytes and granulocytes [3].
• Ly-6I mRNA has been detected in a wide range of tissues and cell lines, and a rabbit polyclonal Ab has been used to determine that Ly-6I protein is present at a low constitutive level on cell lines from several different lineages [3].

Regulatory relationships of Ly6i

• However, Ly-6I is also expressed on immature B cell populations that do not express Ly-6C [3].

Other interactions of Ly6i

• CH27 cells with low levels of Ly-6A/E ligand activity also lost expression of CD22, and cells transfected with CD22 gained the ability to bind the Ly-6A/E chimera and, to a lesser extent, the Ly-6C and Ly-6I chimeric proteins [1].

References